Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06995703 · ClinicalTrials.gov registry record · NA
Increasing Screening for Cancer Using EHR-Nudges Replication
A NA study of Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- NA
- Development phase
- 7,920
- Enrollment target
- 1
- Study location
NCT06995703 is a NA study of Breast Cancer that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 7,920 participants, above the 2,797-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (183% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06995703, a NA study of Breast Cancer, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 7,920 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, personalized nudges to clinicians and patients will be evaluated to help increase breast cancer screening rates in accordance with USPSTF guidelines among women with a primary care visit. In partnership with Penn Medicine (Penn) and Case Western Reserve University-University Hospitals (UH), two complementary, concurrent 6-month, cluster randomized, pragmatic trials were conducted from December 2023 to October 2024. This trial will now replicate those interventions at Lancaster General Health (LGH), incorporating learnings from the primary trials while also adapting to align with existing health system protocols and policies. The patient nudge interventions include pre- and post-visit text message reminders to encourage the patient to schedule their mammogram, and the clinician nudge intervention includes a Smart Data Element message in the electronic health record (EHR) reminding the care team that the patient is overdue and that patients are more likely to complete their screening if recommended and ordered by their clinician.
Conditions Studied
Interventions
- BEHAVIORAL Pre-Visit Patient Text Message
- BEHAVIORAL Post-Visit Patient Text Messages
- BEHAVIORAL Smart Data Element (SDE)
Study Locations (1)
Pennsylvania
- Lancaster General Health - Lancaster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,920 participants |
| Start Date | 2025-06-02 |
| Est. Completion | 2026-06-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06995703
The ClinicalTrials.gov registry entry for NCT06995703 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 7,920 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,797-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (183% higher). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pre-Visit Patient Text Message is the first listed.
NCT06995703 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06995703 about?
NCT06995703 is a clinical study titled "Increasing Screening for Cancer Using EHR-Nudges Replication". In this study, personalized nudges to clinicians and patients will be evaluated to help increase breast cancer screening rates in accordance with USPSTF guidelines among women with a primary care visit. In partnership with Penn Medicine (Penn) and Case Western Reserve University-University Hospitals...
What is the current status of trial NCT06995703?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 7,920 participants. The study started on 2025-06-02. Estimated completion is 2026-06-02.
What conditions does trial NCT06995703 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT06995703?
The interventions under investigation include: Pre-Visit Patient Text Message (BEHAVIORAL), Post-Visit Patient Text Messages (BEHAVIORAL), Smart Data Element (SDE) (BEHAVIORAL).
Who is sponsoring clinical trial NCT06995703?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06995703 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.